

Influenza A+B FIA Rapid Test Device

Catalogue No.: FI2-INF-001

For professional *in vitro* diagnostic use only.

INTENDED USE

The Biopanda Influenza A+B FIA Rapid Test Device is intended for *in vitro* qualitative detection of influenza A and B antigens in nasopharyngeal swab, throat swab, or nasal aspirate specimens. This test is intended to aid in the diagnosis of influenza A and B viral infections.

TEST PRINCIPLE

The Biopanda Influenza A+B FIA Rapid Test Device detects Influenza A and Influenza B nucleoproteins based on Fluorescence Immunoassay. The sample moves through the strip from sample pad to absorbent pad. If the specimen contains Influenza A and/or Influenza B nucleoproteins, it attaches to the fluorescent microspheres-conjugated anti-Influenza A and/or Influenza B antibodies. The complex will then be captured by the capture antibodies coated on the nitrocellulose membrane (Test line). The concentration of Influenza A and/or Influenza B in the sample correlates with the fluorescence signal intensity captured on the test line (T), which can be scanned by the Biopanda Fluorescence Immunoassay Analyser. The testing results will be displayed on the analyser screen.

REAGENTS

The test includes anti-Influenza A and B conjugated fluorophores and anti-Influenza A and B coated on the membrane.

PRECAUTIONS

1. For professional *in vitro* diagnostic use only.
2. Do not use after the expiration date indicated on the package. Do not use the test if the foil pouch is damaged. Do not reuse.
3. Avoid cross-contamination of samples by using a new sample collection container for each sample obtained.
4. Do not eat, drink or smoke in the area where the samples and tests are handled. Handle all samples as if they contain infectious agents. Observe established precautions against microbiological hazards throughout the procedure and follow standard procedures for proper disposal of samples. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when samples are assayed.
5. Do not interchange or mix reagents or ID cards from different lots.
6. Extremes of humidity and temperature can adversely affect results.
7. Used testing materials should be discarded in accordance with local regulations.
8. Read the entire procedure carefully prior to any testing.
9. The Biopanda Influenza A+B FIA Rapid Test should only be used with the Biopanda Fluorescence Immunoassay Analyser by medical professionals.

STORAGE AND STABILITY

1. The kit should be stored at 4-30°C until the expiry date printed on the sealed pouch.
2. The test must remain in the sealed pouch until use.
3. **Do not freeze.**
4. Care should be taken to protect the components of the kit from contamination. Do not use if there is evidence of microbial contamination or precipitation. Biological contamination of dispensing equipment, containers or reagents can lead to false results.

KIT COMPONENTS

Provided:

- 25 x Foil wrapped Influenza A+B tests
- 25 x Extraction tubes and tube tips
- 25 x Sterile swabs
- 1 x Extraction reagent bottle
- 1 x ID card
- 1 x Workstation
- 1 x Package Insert

Required but not provided:

- Timer
- Biopanda Fluorescence Immunoassay Device (BR-FIA-2000)

SAMPLE COLLECTION AND PREPARATION

Collection:

Nasopharyngeal Swab Sample

- Carefully insert the sterile swab into the nostril, parallel to the palate (and not upwards) until resistance is encountered where it has reached the surface of the nasopharynx.
- Gently rub and roll the swab head over against the nasopharynx. Leave the swab in place for several seconds, then slowly withdraw the swab while rotating it.
- If the head of the swab has not been saturated with fluid from the first collection, it can be re-inserted into the other nostril to collect specimens from the other side.

Throat Swab Sample

Insert a sterilized swab into pharynx and collect mucopidermis mainly wiping flare region of the post-pharyngeal wall and palatine tonsil several times, and be careful not to make saliva attach to the swab.

Nasal Aspirate Sample

Connect an aspiration catheter to an aspiration trap that is attached to an aspiration device. Insert the catheter to nasal cavity from a nostril, start the aspiration device and then collect a nasal aspirate sample. Dip a sterilized swab into the collected nasal aspirate sample, ready for sample extraction.

Preparation:

Before performing the test, please bring the sample to room temperature (15-30°C). Cold buffer solution or moisture condensation on the test membrane can lead to invalid test results.

DIRECTIONS FOR USE

Refer to the Biopanda Fluorescence Immunoassay Analyser User Manual for the complete instructions on use of the analyser. The test should be conducted at room temperature.

Allow the test device, swab sample, buffer and/or controls to reach room temperature (15-30°C) prior to testing.

1. Turn on the Analyser.
2. Take out the ID card and insert it into the ID Card Slot. Choose test mode and/or sample type accordingly.
3. Take an extraction tube and place it the designated area of the workstation.
4. Take the extraction reagent bottle and squeeze **10 drops of buffer** (approx. 400 µl) into the extraction tube. Try not to touch the edge of the tube so the buffer drops fall freely.
5. Place the swab specimen into the extraction tube and rotate to swab head against the bottom of the tube for **about 10 seconds**. Remove the swab while squeezing the swab head against the tube to expel as much liquid as possible. **Discard swab in accordance with proper protocol.**
6. Fit the tube tip on top of the extraction tube.
7. Remove the test device from the sealed foil pouch and place it on a clean, level surface. Testing should start within one hour of opening the foil pouch.
8. Add **3 drops of solution** (approx. 120 µl) to the sample well of the test device, and then start the timer.
9. **Test results should be interpreted at 15 minutes** with the use of the Biopanda Fluorescence Immunoassay Analyser.

Note: There are different test modes for the Biopanda Fluorescence Immunoassay: Standard Test mode and Quick Test mode. Please refer to the user manual for more details.

Quick test mode: After 15 minutes of adding the solution, insert the test device into the analyser, select "QUICK TEST" and fill the test information. Select "NEW TEST" and the analyser will automatically display the test result.

Standard test mode: Insert the test device into the analyser immediately after adding the solution, select "STANDARD TEST" and fill the test information. Select "NEW TEST" and the analyser will automatically start a timer for 15 minutes. The analyser will display the test result once the timer ends.

INTERPRETATION OF RESULTS

The test result is calculated by the Biopanda Fluorescence Immunoassay Device and displayed on the analyser screen. For additional information please refer to the user manual.

NOTE: The result displayed on the analyser screen is given as Positive (+) or Negative (-) with a value. This value is calculated by dividing the signal obtained with the sample by the cut-off value (S/C Ratio).

- Test results with a value of ≥ 1.00 are considered positive for Influenza A

and/or B.

- Test results with a value of <1.00 are considered negative for Influenza A and/or B.

QUALITY CONTROL

Each test contains an internal control that satisfies routine quality control requirements. This internal control is performed each time a patient sample is tested. This control indicates that the test device was inserted and read properly by the analyser. An invalid result from the internal control causes an error message to display on the analyser.

Insufficient sample volume or incorrect procedural techniques are the most likely reasons for control failure. Review the procedure and repeat the test with a new test. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

PERFORMANCE CHARACTERISTICS

Sensitivity, Specificity, and Accuracy

The Biopanda Influenza A+B FIA Rapid Test Device has been evaluated with specimens obtained from the patients and compared to RT-PCR as a reference. Specimens were considered positive if RT-PCR indicated a positive result. Specimens were considered negative if RT-PCR indicated a negative result.

Nasopharyngeal Swab Specimen

		Type A			Type B		
		RT-PCR		Total	RT-PCR		Total
		Positive	Negative		Positive	Negative	
Biopanda	Positive	110	2	112	89	2	91
Flu A+B	Negative	102	189	191	2	187	189
	Total	112	191	303	91	189	280
	Relative Sensitivity	98.2%			97.8%		
	Relative Specificity	99.0%			98.9%		
	Accuracy	98.7%			98.6%		

Throat Swab Specimen

		Type A			Type B		
		RT-PCR		Total	RT-PCR		Total
		Positive	Negative		Positive	Negative	
Biopanda	Positive	65	1	66	75	1	76
Flu A+B	Negative	2	135	137	4	199	203
	Total	67	136	203	79	200	279
	Relative Sensitivity	97.0%			94.9%		
	Relative Specificity	99.3%			99.5%		
	Accuracy	98.5%			98.2%		

Nasal Aspirate Specimen

		Type A			Type B		
		RT-PCR		Total	RT-PCR		Total
		Positive	Negative		Positive	Negative	
Biopanda	Positive	49	2	51	89	1	90
Flu A+B	Negative	0	245	245	2	165	167
	Total	49	247	296	91	166	257
	Relative Sensitivity	100%			97.8%		
	Relative Specificity	99.2%			99.4%		
	Accuracy	99.3%			98.8%		

Reactivity with Human Influenza Strains

The Biopanda Influenza A+B FIA Rapid Test Device was tested with the following human influenza strains and a discernible line at appropriate test-line regions was observed:

Influenza A Virus		Influenza B Virus
A/NWS/33 10(H1N1)	A/chicken/Yuyao/2/2006 (H5N1)	B/R5
A/Hong Kong/8/68(H3N2)	A/swine/Hubei/251/2001 (H9N2)	B/Russia/69
A/Port Chalmers/1/73(H3N2)	A/Duck/Hubei/216/1983(H7N8)	B/Lee/40
A/WS/33(H1N1)	A/Duck/Hubei/137/1982(H10N4)	B/Hong Kong/5/72
A/New Jersey/8/76(HswN1)	A/Anhui/1/2013 (H7N9)	
A/Mal/302/54(H1N1)		

Specificity Testing with Various Viral Strains

Description	Test Level
Human adenovirus C	5.62 x 10 ⁵ TCID50/ml
Human adenovirus B	1.58 x 10 ⁴ TCID50/ml
Adenovirus type 10	3.16 x 10 ³ TCID50/ml
Adenovirus type 18	1.58 x 10 ⁴ TCID50/ml
Human coronavirus OC43	2.45 x 10 ⁶ LD50/ml
Coxsackievirus A9	2.65 x 10 ⁴ LD50/ml
Coxsackievirus B5	1.58 x 10 ⁵ TCID50/ml
Human herpesvirus 5	1.58 x 10 ⁴ TCID50/ml
Echovirus 2	3.16 x 10 ⁵ TCID50/ml
Echovirus 3	1 x 10 ⁴ TCID50/ml
Echovirus 6	3.16 x 10 ⁶ TCID50/ml
Herpes simplex virus 1	1.58 x 10 ⁵ TCID50/ml
Human herpesvirus 2	2.81 x 10 ⁵ TCID50/ml

Human Rhinovirus 2	2.81 x 10 ⁴ TCID50/ml
Human Rhinovirus 14	1.58 x 10 ⁶ TCID50/ml
Human Rhinovirus 16	8.89 x 10 ⁶ TCID50/ml
Measles	1.58 x 10 ⁴ TCID50/ml
Mumps	1.58 x 10 ⁴ TCID50/ml
Sendai virus	8.89 x 10 ⁴ TCID50/ml
Parainfluenza virus 2	1.58 x 10 ⁷ TCID50/ml
Parainfluenza virus 3	1.58 x 10 ⁸ TCID50/ml
Respiratory syncytial virus	8.89 x 10 ⁴ TCID50/ml
Human respiratory syncytial virus	1.58 x 10 ⁵ TCID50/ml
Rubella	2.81 x 10 ⁵ TCID50/ml
Varicella-Zoster	1.58 x 10 ³ TCID50/ml

TCID50 = Tissue Culture Infectious Dose is the dilution of virus that under the conditions of the assay can be expected to infect 50% of the culture vessels inoculated.

LD50 = Lethal Dose is the dilution of virus that under the conditions of the assay can be expected to kill 50% of the suckling mice inoculated.

Precision

Intra-assay and Inter-assay

Within-run and Between-run precision has been determined by using five specimens of influenza standard control. Three different lots of the Biopanda Influenza A+B FIA Rapid Test Device were tested using negative, Influenza A weak, Influenza B weak, Influenza A strong, and Influenza B strong samples. Ten replicates of each level were tested each day for 3 consecutive days. The specimens were correctly identified >99% of the time.

Cross-reactivity

The following organisms were tested at 1.0x10⁸org/ml and all found to be negative when tested with the Biopanda Influenza A+B FIA Rapid Test Device:

<i>Arcanobacterium</i>	<i>Pseudomonas aeruginosa</i>
<i>Candida albicans</i>	<i>Staphylococcus aureus subspecies aureus</i>
<i>Corynebacterium</i>	<i>Staphylococcus epidermidis</i>
<i>Enterococcus faecalis</i>	<i>Staphylococcus saprophylicus</i>
<i>Enterococcus faecium</i>	<i>Streptococcus agalactiae</i>
<i>Escherichia coli</i>	<i>Streptococcus bovis</i>
<i>Haemophilus</i>	<i>Streptococcus dysgalactiae/subsp.dysgalactiae</i>
<i>Moraxella catarrhalis</i>	<i>Streptococcus oralis</i> formerly <i>Streptococcus</i>
<i>Neisseria gonorrhoeae</i>	<i>Streptococcus pneumoniae</i>
<i>Neisseria lactamica</i>	<i>Streptococcus pyogenes</i>
<i>Neisseria subflava</i>	<i>Streptococcus salivarius</i>
<i>Proleus vulgaris</i>	<i>Streptococcus sp group F.type 2</i>

LIMITATIONS OF THE TEST

1. The Biopanda Influenza A+B FIA Rapid Test Device is for professional *in vitro* diagnostic use only, for the qualitative detection of Influenza A and/or B virus in nasopharyngeal swab, throat swab, or nasal aspirate specimens. It should be used only with the analyser.
2. The test will only indicate the presence of influenza A and/or B virus in the specimen from both viable and non-viable strains.
3. As with all diagnostic tests, a confirmed diagnosis should only be made by a physician after all clinical and laboratory findings have been evaluated. This test should not be the sole criterion for treatment decisions.
4. Excess blood or mucus on the swab specimen may interfere with test performance and may field a false positive result.
5. The accuracy of the test depends on the quality of the swab sample. False negatives may result from improper sample collection or storage.
6. The use of over-the-counter and prescription nasal sprays at high concentrations can interfere with results, leading to either invalid or incorrect test results.
7. A positive result for influenza A and/or B does not preclude an underlying co-infection with another pathogen, therefore the possibility of an underlying bacterial infection should be considered.

Thank you for purchasing Biopanda's Influenza A+B FIA Rapid Test Device. Please read this manual carefully before operating to ensure proper use.



Biopanda Reagents Ltd.

Unit 14 Carrowreagh Business Park
Carrowreagh Road
Belfast, BT16 1QQ
United Kingdom
Tel: +44 (0) 28 95438774
E-mail: info@biopanda.co.uk
Website: www.biopanda.co.uk

Revision Date: 21/01/2025